aTyr Pharma, Inc. (LIFE) Stock Rating Reaffirmed by BMO Capital Markets

BMO Capital Markets reissued their hold rating on shares of aTyr Pharma, Inc. (NASDAQ:LIFE) in a report released on Wednesday, May 24th.

Several other equities analysts have also recently weighed in on LIFE. J P Morgan Chase & Co reiterated a hold rating on shares of aTyr Pharma in a report on Saturday, March 18th. Citigroup Inc. boosted their target price on aTyr Pharma from $3.00 to $4.00 and gave the company a neutral rating in a research note on Monday, March 20th.

aTyr Pharma (NASDAQ LIFE) traded up 5.97% during mid-day trading on Wednesday, hitting $3.55. 13,021 shares of the stock were exchanged. The firm has a 50-day moving average price of $3.33 and a 200-day moving average price of $3.19. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $4.45. The stock’s market capitalization is $84.51 million.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Equities analysts predict that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “aTyr Pharma, Inc. (LIFE) Stock Rating Reaffirmed by BMO Capital Markets” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/06/16/atyr-pharma-inc-life-receives-hold-rating-from-bmo-capital-markets-2-updated-updated.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC raised its position in aTyr Pharma by 134.7% in the first quarter. EcoR1 Capital LLC now owns 2,292,659 shares of the biotechnology company’s stock worth $8,024,000 after buying an additional 1,315,673 shares during the last quarter. Renaissance Technologies LLC raised its position in aTyr Pharma by 1.8% in the first quarter. Renaissance Technologies LLC now owns 38,800 shares of the biotechnology company’s stock worth $136,000 after buying an additional 700 shares during the last quarter. Dimensional Fund Advisors LP raised its position in aTyr Pharma by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 58,172 shares of the biotechnology company’s stock worth $204,000 after buying an additional 2,800 shares during the last quarter. Geode Capital Management LLC raised its position in aTyr Pharma by 0.4% in the first quarter. Geode Capital Management LLC now owns 112,178 shares of the biotechnology company’s stock worth $392,000 after buying an additional 444 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in aTyr Pharma by 22.0% in the first quarter. Vanguard Group Inc. now owns 435,324 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 78,579 shares during the last quarter. 47.14% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply